Results 191 to 200 of about 240,975 (267)

Clinical characteristics of community acquired pneumonia due to <i>Mycoplasma pneumoniae:</i> experience from an outbreak. [PDF]

Infez Med
Nair AA, Niyas VKM, Ananthanarayanan R, Durai SC, Jose D, Padmanabhan A.   +5 more
europepmc   +1 more source

Mycoplasma pneumonia

, 2013
Yuranga Weerakkody, Liz Silverstone, Craig Hacking   +2 more
openaire   +1 more source

In the shadow of COVID-19: changes in the seroprevalence of pediatric Mycoplasma pneumoniae. [PDF]

BMC Infect Dis
Geng H, Wang X, Rayburn ER, Wang Q, Bao X, Hu R, Li H.   +6 more
europepmc   +1 more source

<i>Mycoplasma pneumoniae</i>-Associated Mucositis: A Diagnostic Dilemma. [PDF]

Clin Case Rep
Mathur M, Paudel S, Bhattarai N, Karki S, Maharjan S, Regmi S.   +5 more
europepmc   +1 more source

Soluble ST2 as a biomarker for predicting severe adverse events among pediatric patients with Mycoplasma pneumoniae pneumonia. [PDF]

PLoS One
Cheng F, Li T, Zhang L, Xu M, Chen L, Ye Z, Xu J.   +6 more
europepmc   +1 more source

The impact of the COVID-19 pandemic on the epidemiology, clinical manifestations and molecular characteristics of <i>Mycoplasma pneumoniae</i>. [PDF]

Front Immunol
Yan L, Fu H, Zhang H, Dong H, Chen J, Yu L, Zhang L.   +6 more
europepmc   +1 more source

Antimicrobial Susceptibility and Distribution Characteristics of <i>Mycoplasma pneumoniae</i> Isolates in Beijing, China, from 2017 to 2025. [PDF]

Pharmaceuticals (Basel)
Yan C, Chen Y, Su A, Liu X, Jia X, Ren X, Zhao H, Feng Y, Cui J, Sun Y, Zhao L, Yuan J.   +11 more
europepmc   +1 more source

Genomic-Based Epidemiological Analysis of the Post-Pandemic <i>Mycoplasma pneumoniae</i> Resurgence. [PDF]

MedComm (2020)
Liu H, Zheng X, Du X, Wang Y, Xiang Y, Wang Q, Tian S, Xian Y, Chen W, Liu H, Wang H, Wang C, Yang M, Jia H, Li X, Dan Y, Tong L, Deng G, Li H, Wang F, Song H, Qiu S.   +21 more
europepmc   +1 more source